Insights

Gathering insights about Neol…

Similar companies to Neol

Neol Tech Stack

Neol uses 8 technology products and services including Amazon Web Services, Cloudflare, Google Cloud, and more. Explore Neol's tech stack below.

Amazon Web Services
Cloud Hosting
Cloudflare
Content Management System
Google Cloud
Infrastructure As A Service
Zapier
IT Infrastructure
HubSpot Chat
Live Chat
Webflow
Page Builders
PayPal
Payment Processing
JavaScript
Programming Languages

Media & News

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbol "NGNE" following the anticipated closing of the merger with Neurogene Inc. (the “Merger”), with a new CUSIP number 64135M105. The reverse stock split was effected to ensure the combined company's compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Global Market. The reverse stock split was approved by Neoleukin's stockholders at the Company's special meeting of stockholders held on December 13, 2023, to be effected in the Board's discretion within approved parameters of not less than 1-for-1.5 and not more than 1-for-5. The final reverse stock split ratio was approved by the Board on December 13, 2023. The reverse stock split is expected to reduce the number of shares of the Company's outstanding common stock from approximately 9,398,497 shares to approximately 2,349,624 shares. The number of shares of the Company's authorized common stock was not affected by the reverse stock split, but at the special meeting of stockholders, Neoleukin's stockholders approved an increase in the number of shares of the Company's authorized common stock from 20,000,000 shares to 500,000,000 shares in connection with the anticipated closing of the Merger. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Neoleukin's common stock underlying the Company's outstanding equity awards and pre-funded warrants for common stock, as well as the number of shares of common stock issuable under the Company's equity incentive plan and employee stock purchase plan. There will be no change to the par value per share.
Dec 14, 2023 | www.globenewswire.com
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol “NLTX” with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
Sep 22, 2023 | www.globenewswire.com
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of both Redmile Group and Neoleukin Therapeutics, and an evaluation of the latter's financial health and industry position.
Jul 27, 2023 | www.gurufocus.com
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin Therapeutics, Inc. (NasdaqCM: NLTX) with Neurogene Inc. Under the terms of the proposed transaction, pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company (subject to certain adjustments) and will also be issued contingent value rights to receive certain pa.
Jul 25, 2023 | www.businesswire.com
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene. Click here to learn how to join the action https://www.ademilaw.com/case/neoleukin-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
Jul 18, 2023 | www.prnewswire.com
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin shareholders. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Neoleukin shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.
Jul 18, 2023 | www.businesswire.com
Neurogene and Neoleukin Announce Definitive Merger Agreement
NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene's pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon completion of the merger, which is subject to approval by Neurogene and Neoleukin stockholders, the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”.
Jul 18, 2023 | www.globenewswire.com

Neol's Email Address Formats

Neol uses at least 2 format(s):

Neol Email Formats	Example	Percentage
First@neol.co	John@neol.co	94%
Middle@neol.co	Michael@neol.co	6%

Frequently Asked Questions

Where is Neol's headquarters located?

Neol's main headquarters is located at London, GB. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Neol's stock symbol?

Neol is a publicly traded company; the company's stock symbol is NLTX.

What is Neol's official website and social media links?

Neol's official website is neol.ai and has social profiles on LinkedIn Crunchbase.

What is Neol's NAICS code?

Neol's NAICS code is 5112 - Software Publishers.

How many employees does Neol have currently?

As of October 2025, Neol has approximately 154 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Co-Founder & Ceo: K. A.Co-Founder: A. S.Co-Founder & Coo: A. Ş.. Explore Neol's employee directory with LeadIQ.

What industry does Neol belong to?

Neol operates in the Software Development industry.

What technology does Neol use?

Neol's tech stack includes Amazon Web ServicesCloudflareGoogle CloudZapierHubSpot ChatWebflowPayPalJavaScript.

What is Neol's email format?

Neol's email format typically follows the pattern of First@neol.co. Find more Neol email formats with LeadIQ.

When was Neol founded?

Neol was founded in 2022.

Neol

Q: What is Neol's official website and social media links?

Neol's official website is neol.ai. Neol has social profiles on LinkedIn.

Q: How many employees does Neol have currently?

Neol has approximately 154 employees.

Q: What technology does Neol use?

Neol's tech stack includes HSTS, Google Analytics, React, Google App Engine, Hotjar.

Software DevelopmentLondon, United Kingdom51-200 Employees

Find the right people for any role, project, or collaboration.

Whether you’re hiring for roles, recruiting for project work, or looking for collaborators, Neol connects you with the right person.

Neol is trusted by leading startups, enterprises, and public institutions alike for diverse talent search and network management needs.

—Bring your entire talent ecosystem into one place
Manage internal teams, collaborators, and partner networks in one centralized space with advanced AI tools.

—Find the best fit for any role or project
Search across your network or globally to identify top matches for any role or project.

—Review with AI to evaluate candidates for specific roles
Easily evaluate a candidate’s past experience and skills for any brief, role, or project.

—Manage roles, offers, projects, collaborations
Create shared or private briefs, projects, and lists to organize and contact candidates.